Amedeo Smart

Free Medical Literature Service


 

Amedeo

Diabetes

  Free Subscription

Articles published in
Ann Intern Med
    July 2021
  1. RAJAGOPAL S, Cheskin LJ
    In overweight or obese adults without diabetes, semaglutide increased weight loss and GI disorders.
    Ann Intern Med. 2021 Jul 6. doi: 10.7326/ACPJ202107200.
    >> Share

    June 2021
  2. SZAREK M, Bhatt DL, Steg PG, Cannon CP, et al
    Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure : A Randomized Trial.
    Ann Intern Med. 2021 Jun 22. doi: 10.7326/M21-0651.
    >> Share

  3. CENTOR RM, Tuttle KR, Himmelfarb J
    Annals On Call - SGLT-2 Revisited: Diabetes Management in Chronic Kidney Disease.
    Ann Intern Med. 2021 Jun 1. doi: 10.7326/A20-0014.
    >> Share

  4. TANNER M
    In type 2 diabetes, SGLT2 inhibitors reduce all-cause, but not cardiovascular, mortality vs. GLP-1 RAs.
    Ann Intern Med. 2021 Jun 1. doi: 10.7326/ACPJ202106150.
    >> Share

  5. SARMA S, Lipscombe LL
    In obesity with T2DM, biliopancreatic diversion increased T2DM remission vs. medical and lifestyle therapy at 10 y.
    Ann Intern Med. 2021;174:JC70.
    >> Share

    May 2021

  6. Correction: Type 2 Diabetes.
    Ann Intern Med. 2021;174:735.
    >> Share

  7. KOHN OF
    SGLT2 inhibitors reduce all-cause mortality.
    Ann Intern Med. 2021;174:JC52.
    >> Share

  8. KOHN OF
    In CKD, the effect of dapagliflozin on kidney outcomes did not vary by T2DM status or CKD cause.
    Ann Intern Med. 2021;174:JC53.
    >> Share

  9. GRIFFIN TP, Dinneen SF
    In men who are overweight or obese, adding testosterone therapy reduced glucose intolerance/T2DM.
    Ann Intern Med. 2021;174:JC54.
    >> Share

    March 2021
  10. KARAGIANNIS T, Tsapas A, Bekiari E
    KDIGO made 12 recommendations for managing diabetes with CKD.
    Ann Intern Med. 2021 Mar 2. doi: 10.7326/ACPJ202103160.
    >> Share

  11. GRIFFIN TP, Dinneen SF
    In T2DM, weekly insulin icodec did not differ from daily glargine for reducing HbA1c or significant/severe hypoglycemia.
    Ann Intern Med. 2021;174:JC34.
    >> Share

    February 2021
  12. SMETANA GW, Tetrault JM, Hill KP, Burns RB, et al
    Should You Recommend Cannabinoids for This Patient With Painful Neuropathy? : Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
    Ann Intern Med. 2021 Feb 9. doi: 10.7326/M20-7945.
    >> Share

    January 2021
  13. GREGORY JM, Moore DJ
    The Dual Burden of Type 1 Diabetes and COVID-19.
    Ann Intern Med. 2021 Jan 26. doi: 10.7326/M21-0367.
    >> Share

  14. KABADI UM
    Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes.
    Ann Intern Med. 2021;174:140.
    >> Share

  15. TSAPAS A, Karagiannis T, Avgerinos I, Matthews DR, et al
    Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes.
    Ann Intern Med. 2021;174:141.
    >> Share

  16. HAO Q, Guyatt G
    Efficacy and safety of dapagliflozin were similar in patients with type 2 DM and atherosclerotic CVD, regardless of PAD.
    Ann Intern Med. 2021;174:JC10.
    >> Share

  17. HAO Q, Guyatt G
    Newly prescribed canagliflozin vs. GLP-1 agonists was linked to amputation in older adults with type 2 DM and CVD.
    Ann Intern Med. 2021;174:JC11.
    >> Share

  18. KIM NH, Siddiqui M, Vogel J
    MELAS Syndrome and MIDD Unmasked by Metformin Use: A Case Report.
    Ann Intern Med. 2021;174:124-125.
    >> Share

    December 2020
  19. LIAKOS A, Tsapas A, Bekiari E
    In type 2 diabetes, SGLT2 inhibitors were linked to diabetic ketoacidosis vs. DPP-4 inhibitors.
    Ann Intern Med. 2020;173:JC70.
    >> Share

  20. HICKS CW, Wang D, Matsushita K, Windham BG, et al
    Peripheral Neuropathy and All-Cause and Cardiovascular Mortality in U.S. Adults : A Prospective Cohort Study.
    Ann Intern Med. 2020 Dec 8. doi: 10.7326/M20-1340.
    >> Share

    November 2020
  21. GANDHI GY
    In type 2 diabetes, some glucose-lowering drugs reduce HbA1c more than others; drugs do not differ for mortality.
    Ann Intern Med. 2020;173:JC53.
    >> Share

  22. TANNER M
    In type 2 diabetes, GLP-1 RA plus SGLT2 inhibitor vs. either drug alone reduces HbA1c and SBP and may reduce body weight.
    Ann Intern Med. 2020;173:JC52.
    >> Share

  23. OLSON DE
    In older adults with type 1 diabetes, continuous glucose monitoring reduced hypoglycemia over 6 months.
    Ann Intern Med. 2020;173:JC54.
    >> Share

  24. PALASKAS NL, Deswal A
    In heart failure, adding empagliflozin to medical therapy reduced a composite of CV death or HF hospitalization.
    Ann Intern Med. 2020;173:JC51.
    >> Share

  25. NAVANEETHAN SD, Zoungas S, Caramori ML, Chan JCN, et al
    Diabetes Management in Chronic Kidney Disease: Synopsis of the 2020 KDIGO Clinical Practice Guideline.
    Ann Intern Med. 2020 Nov 10. doi: 10.7326/M20-5938.
    >> Share

  26. DOUMOURAS AG, Hong D, Lee Y, Tarride JE, et al
    Association Between Bariatric Surgery and All-Cause Mortality: A Population-Based Matched Cohort Study in a Universal Health Care System.
    Ann Intern Med. 2020;173:694-703.
    >> Share

    October 2020
  27. GRIFFIN TP, Dinneen SF
    SGLT2 inhibitors increase risk for diabetic ketoacidosis in type 2 diabetes.
    Ann Intern Med. 2020;173:JC40.
    >> Share

  28. BRAILOVSKI E, Kim RB, Juurlink D
    Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case Report.
    Ann Intern Med. 2020;173:585-587.
    >> Share

    September 2020

  29. Correction: Long-Term Weight Loss With Metformin or Lifestyle Intervention in the Diabetes Prevention Program Outcomes Study.
    Ann Intern Med. 2020;173:508.
    >> Share

  30. YOSHIDA K, Sakamoto N, Kurosaka D
    Improvement in Polymyalgia Rheumatica Associated With Improved Control of Diabetes Mellitus: A Case Series.
    Ann Intern Med. 2020 Sep 15. doi: 10.7326/L20-0196.
    >> Share

  31. DOYLE-DELGADO K, Chamberlain JJ, Shubrook JH, Skolnik N, et al
    Pharmacologic Approaches to Glycemic Treatment of Type 2 Diabetes: Synopsis of the 2020 American Diabetes Association's Standards of Medical Care in Diabetes Clinical Guideline.
    Ann Intern Med. 2020 Sep 1. doi: 10.7326/M20-2470.
    >> Share

  32. VUKOTIC R, Raimondi F, Brodosi L, Vitale G, et al
    The Effect of Liraglutide on beta-Blockade for Preventing Variceal Bleeding: A Case Series.
    Ann Intern Med. 2020;173:404-405.
    >> Share

    August 2020
  33. TARTOF SY, Qian L, Hong V, Wei R, et al
    Obesity and Mortality Among Patients Diagnosed With COVID-19: Results From an Integrated Health Care Organization.
    Ann Intern Med. 2020 Aug 12. doi: 10.7326/M20-3742.
    >> Share

    July 2020
  34. DOUROS A, Lix LM, Fralick M, Dell'Aniello S, et al
    Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis: A Multicenter Cohort Study.
    Ann Intern Med. 2020 Jul 28. doi: 10.7326/M20-0289.
    >> Share

  35. LOOMIS E, Bajwa J, Kaizuka S
    Buprenorphine-Naloxone as a Novel Treatment of Narcotic Bowel Syndrome: A Case Report.
    Ann Intern Med. 2020;173:164-166.
    >> Share

    June 2020
  36. LEE CG, Cefalu WT
    The Right Diabetes Medication for the Right Patient for the Right Outcome: Can a Network Meta-analysis Help Us Decide?
    Ann Intern Med. 2020 Jun 30. doi: 10.7326/M20-4266.
    >> Share

  37. TSAPAS A, Avgerinos I, Karagiannis T, Malandris K, et al
    Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.
    Ann Intern Med. 2020 Jun 30. doi: 10.7326/M20-0864.
    >> Share

    May 2020
  38. TIAN S, Wu J, Liu JS, Zou BS, et al
    Type 2 Diabetes.
    Ann Intern Med. 2020;172:704-705.
    >> Share

  39. VIJAN S
    Type 2 Diabetes.
    Ann Intern Med. 2020;172:705.
    >> Share


  40. Correction: In the Clinic: Type 2 Diabetes.
    Ann Intern Med. 2020;172:708.
    >> Share

    April 2020
  41. TANNER M
    In screen-detected type 2 diabetes, intensive therapy did not differ from usual care for CV events at 10 years.
    Ann Intern Med. 2020;172:JC41.
    >> Share

  42. CHARI ST, Sharma A, Maitra A
    Early Detection of Sporadic Pancreatic Ductal Adenocarcinoma: Problems, Promise, and Prospects.
    Ann Intern Med. 2020;172:558-559.
    >> Share

    March 2020
  43. KLOECKER DE, Davies MJ, Khunti K, Zaccardi F, et al
    Uses and Limitations of the Restricted Mean Survival Time: Illustrative Examples From Cardiovascular Outcomes and Mortality Trials in Type 2 Diabetes.
    Ann Intern Med. 2020 Mar 24. pii: 2763641. doi: 10.7326/M19-3286.
    >> Share

  44. LIAKOS A, Liakopoulou P, Tsapas A
    Cyclical pressurized topical wound oxygen therapy increased healing of refractory diabetic foot ulcers.
    Ann Intern Med. 2020;172:JC27.
    >> Share

    February 2020
  45. BROWN K, Donato AA
    In type 2 diabetes, early metformin plus vildagliptin reduced treatment failure vs a stepwise approach.
    Ann Intern Med. 2020;172:JC23.
    >> Share

  46. AI NG SY, Zhu D, Herrington WG
    In type 2 diabetes, SGLT-2 inhibitors reduce risk for major kidney outcomes.
    Ann Intern Med. 2020;172:JC18.
    >> Share

    January 2020
  47. RACO DL
    In stable CAD with type 2 diabetes, adding ticagrelor to aspirin reduced CV events but increased major bleeding.
    Ann Intern Med. 2020;172:JC4.
    >> Share

  48. FRALICK M, Chen SK, Patorno E, Kim SC, et al
    Assessing the Risk for Gout With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Population-Based Cohort Study.
    Ann Intern Med. 2020 Jan 14. pii: 2758844. doi: 10.7326/M19-2610.
    >> Share

    December 2019
  49. DAVE CV, Schneeweiss S, Kim D, Fralick M, et al
    Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections.
    Ann Intern Med. 2019;171:944-945.
    >> Share

  50. SARAFIDIS P, Papagianni A
    Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections.
    Ann Intern Med. 2019;171:943-944.
    >> Share

  51. BENJAMIN T, Schumacher C
    Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections.
    Ann Intern Med. 2019;171:944.
    >> Share

  52. CENTOR RM, Ovalle F
    Web Exclusive. Annals On Call - Technology to Improve Diabetes Management.
    Ann Intern Med. 2019;171:OC1.
    >> Share

    November 2019
  53. VIJAN S
    Type 2 Diabetes.
    Ann Intern Med. 2019;171:ITC65-ITC80.
    >> Share

    October 2019
  54. MOIST L
    Dapagliflozin reduced cardiorenal outcomes but not MACE in T2 diabetes with or at risk for atherosclerotic CVD.
    Ann Intern Med. 2019;171:JC43.
    >> Share

  55. SMETANA GW, Nathan DM, Dugdale DC, Burns RB, et al
    To What Target Hemoglobin A1c Level Would You Treat This Patient With Type 2 Diabetes?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
    Ann Intern Med. 2019;171:505-513.
    >> Share

    September 2019
  56. SANTULLI G
    In type 2 diabetes, intensive glucose control for 5.6 years did not differ from usual care for major CV events at 14 years.
    Ann Intern Med. 2019;171:JC31.
    >> Share

  57. EL KAWKGI OM, Montori VM
    In high-risk type 1 diabetes, insulin pumps with suspend-before-low technology reduced hypoglycemic events.
    Ann Intern Med. 2019;171:JC30.
    >> Share

  58. LIPSCOMBE LL
    In poorly controlled type 2 diabetes, oral semaglutide was noninferior to liraglutide for reducing HbA1c.
    Ann Intern Med. 2019;171:JC29.
    >> Share

  59. LIPSCOMBE LL
    In patients >/= 50 years with type 2 diabetes and CV disease or risk factors, oral semaglutide did not increase CV events.
    Ann Intern Med. 2019;171:JC28.
    >> Share

  60. LIPSCOMBE LL
    In patients >/= 50 years with type 2 diabetes and CV disease or risk factors, dulaglutide reduced CV outcomes.
    Ann Intern Med. 2019;171:JC27.
    >> Share

    August 2019
  61. GOEL A
    In type 2 diabetes, a primary care-led weight management program increased weight loss and diabetes remission at 2 years.
    Ann Intern Med. 2019;171:JC17.
    >> Share

  62. LIPSCOMBE LL
    In uncontrolled type 2 diabetes, adjunctive semaglutide reduced HbA1c and body weight vs sitagliptin.
    Ann Intern Med. 2019;171:JC16.
    >> Share

  63. PATEL T
    Canagliflozin reduced kidney failure and CV events at 2.6 years in type 2 diabetes with chronic kidney disease.
    Ann Intern Med. 2019;171:JC15.
    >> Share

  64. CHAMBERLAIN JJ, Doyle-Delgado K, Peterson L, Skolnik N, et al
    Diabetes Technology: Review of the 2019 American Diabetes Association Standards of Medical Care in Diabetes.
    Ann Intern Med. 2019 Aug 13. pii: 2748278. doi: 10.7326/M19-1638.
    >> Share

  65. WHARAM JF, Newhouse JP
    High-Deductible Insurance and Delay in Care.
    Ann Intern Med. 2019;171:226.
    >> Share

  66. GOULET M, Goldstein J
    High-Deductible Insurance and Delay in Care.
    Ann Intern Med. 2019;171:226.
    >> Share

    July 2019
  67. FILION KB, Yu OH
    Sodium-Glucose Cotransporter-2 Inhibitors and Severe Urinary Tract Infections: Reassuring Real-World Evidence.
    Ann Intern Med. 2019 Jul 30. pii: 2739787. doi: 10.7326/M19-1950.
    >> Share

  68. JACKSON GL, Smith VA, Edelman D, Hendrix CC, et al
    Intermediate Diabetes Outcomes in Patients Managed by Physicians, Nurse Practitioners, or Physician Assistants.
    Ann Intern Med. 2019;171:145.
    >> Share

  69. KUMAR PD
    Intermediate Diabetes Outcomes in Patients Managed by Physicians, Nurse Practitioners, or Physician Assistants.
    Ann Intern Med. 2019;171:144.
    >> Share

  70. GROTE J
    Intermediate Diabetes Outcomes in Patients Managed by Physicians, Nurse Practitioners, or Physician Assistants.
    Ann Intern Med. 2019;171:144-145.
    >> Share

  71. KE C, Shah BR, Stukel TA, Chan JCN, et al
    Excess Burden of Mental Illness and Hospitalization in Young-Onset Type 2 Diabetes.
    Ann Intern Med. 2019;171:78-79.
    >> Share

  72. FINUCANE TE
    Excess Burden of Mental Illness and Hospitalization in Young-Onset Type 2 Diabetes.
    Ann Intern Med. 2019;171:78.
    >> Share

    May 2019
  73. MERLI GJ, Weitz HH
    Web Exclusive. Annals Consult Guys - Cardiovascular Risk, Blood Pressure, and Cognition in a Patient With Diabetes.
    Ann Intern Med. 2019;170:CG1.
    >> Share

  74. GOEL A
    Review: Viscous fiber reduces HbA1c, fasting glucose, and insulin resistance in type 2 diabetes.
    Ann Intern Med. 2019;170:JC51.
    >> Share

    April 2019
  75. LUDVIGSSON JF, Neovius M, Soderling J, Gudbjornsdottir S, et al
    Maternal Glycemic Control in Type 1 Diabetes and the Risk for Preterm Birth: A Population-Based Cohort Study.
    Ann Intern Med. 2019 Apr 23. pii: 2731602. doi: 10.7326/M18-1974.
    >> Share

  76. APOLZAN JW, Venditti EM, Edelstein SL, Knowler WC, et al
    Long-Term Weight Loss With Metformin or Lifestyle Intervention in the Diabetes Prevention Program Outcomes Study.
    Ann Intern Med. 2019 Apr 23. pii: 2731601. doi: 10.7326/M18-1605.
    >> Share

  77. KANSAGARA D, Humphrey LL, Qaseem A
    World Health Organization Guidelines on Medicines for Diabetes Treatment Intensification.
    Ann Intern Med. 2019;170:583-584.
    >> Share

  78. GOOD CB, Kolb NR, Meyer M
    World Health Organization Guidelines on Medicines for Diabetes Treatment Intensification.
    Ann Intern Med. 2019;170:583.
    >> Share

  79. PUNTHAKEE Z
    In type 2 diabetes with periodontitis, intensive periodontitis treatment improved glycemic control at 1 year.
    Ann Intern Med. 2019;170:JC40.
    >> Share

  80. DAVIDSON MB
    Review: Rapid-acting analogues do not differ from regular human insulin for mortality or HbA1c in type 2 diabetes.
    Ann Intern Med. 2019;170:JC39.
    >> Share

  81. ARTERBURN D
    Microvascular Outcomes in Patients With Diabetes After Bariatric Surgery.
    Ann Intern Med. 2019;170:507-508.
    >> Share

  82. KWON Y, Park S
    Microvascular Outcomes in Patients With Diabetes After Bariatric Surgery.
    Ann Intern Med. 2019;170:507.
    >> Share

  83. CARLSSON L, Carlsson B, Peltonen M
    Microvascular Outcomes in Patients With Diabetes After Bariatric Surgery.
    Ann Intern Med. 2019;170:506-507.
    >> Share

    January 2019
  84. KE C, Lau E, Shah BR, Stukel TA, et al
    Excess Burden of Mental Illness and Hospitalization in Young-Onset Type 2 Diabetes: A Population-Based Cohort Study.
    Ann Intern Med. 2019 Jan 15. pii: 2720956. doi: 10.7326/M18-1900.
    >> Share

    December 2018

  85. Correction: Glycemic Targets for Older Adults With Type 2 Diabetes.
    Ann Intern Med. 2018;169:899.
    >> Share

  86. SANTULLI G
    In diabetes with no CVD, aspirin reduced serious vascular events but increased major bleeding at 7.4 years.
    Ann Intern Med. 2018;169:JC67.
    >> Share

    November 2018
  87. JACKSON GL, Smith VA, Edelman D, Woolson SL, et al
    Intermediate Diabetes Outcomes in Patients Managed by Physicians, Nurse Practitioners, or Physician Assistants: A Cohort Study.
    Ann Intern Med. 2018 Nov 20. pii: 2716077. doi: 10.7326/M17-1987.
    >> Share

  88. WHARAM JF, Lu CY, Zhang F, Callahan M, et al
    High-Deductible Insurance and Delay in Care for the Macrovascular Complications of Diabetes.
    Ann Intern Med. 2018 Nov 20. pii: 2716078. doi: 10.7326/M17-3365.
    >> Share


  89. The Effect of High-Deductible Insurance Plans on Diabetes Care.
    Ann Intern Med. 2018 Nov 20. pii: 2716396. doi: 10.7326/P18-0018.
    >> Share


  90. Comparing Diabetes Outcomes for Primary Care Provided by Physicians, Nurse Practitioners, and Physician Assistants.
    Ann Intern Med. 2018 Nov 20. pii: 2715823. doi: 10.7326/P18-0017.
    >> Share

  91. TANNER M
    Risk scores overestimated risk for CVD in newly diagnosed type 2 diabetes.
    Ann Intern Med. 2018;169:JC59.
    >> Share

    September 2018
  92. CENTOR RM, Barry MJ
    Web Exclusive. Annals On Call - Oral Pharmacologic Therapy in Type 2 Diabetes: Choosing Therapy Wisely.
    Ann Intern Med. 2018;169:OC1.
    >> Share

  93. HUMPHREY LL, Kansagara D, Qaseem A
    World Health Organization Guidelines on Medicines for Diabetes Treatment Intensification: Commentary From the American College of Physicians High Value Care Committee.
    Ann Intern Med. 2018 Sep 4. pii: 2698899. doi: 10.7326/M18-1148.
    >> Share

  94. ROGLIC G, Norris SL
    Medicines for Treatment Intensification in Type 2 Diabetes and Type of Insulin in Type 1 and Type 2 Diabetes in Low-Resource Settings: Synopsis of the World Health Organization Guidelines on Second- and Third-Line Medicines and Type of Insulin for the
    Ann Intern Med. 2018 Sep 4. pii: 2698900. doi: 10.7326/M18-1149.
    >> Share

  95. CENTOR RM, Montori VM
    Web Exclusive. Annals On Call - Glycemic Control in Type 2 Diabetes: How Low Should We Go?
    Ann Intern Med. 2018;169:OC1.
    >> Share

    August 2018

  96. Prevention of Diabetes With Mediterranean Diets.
    Ann Intern Med. 2018;169:271-272.
    >> Share

  97. O'BRIEN R, Johnson E, Haneuse S, Coleman KJ, et al
    Microvascular Outcomes in Patients With Diabetes After Bariatric Surgery Versus Usual Care: A Matched Cohort Study.
    Ann Intern Med. 2018 Aug 7. pii: 2696493. doi: 10.7326/M17-2383.
    >> Share


  98. Outcomes of Bariatric Surgery in Patients With Diabetes.
    Ann Intern Med. 2018 Aug 7:1. doi: 10.7326/P18-0012.
    >> Share

    July 2018
  99. EGAN AM, Montori VM
    Review: In adults with type 1 diabetes, SGLT-2 inhibitors reduce HbA1c but increase diabetic ketoacidosis.
    Ann Intern Med. 2018;169:JC3.
    >> Share

  100. EGAN AM, Montori VM
    Review: In type 2 diabetes, SGLT-2 inhibitors or GLP-1 agonists reduce mortality vs control or DPP-4 inhibitors.
    Ann Intern Med. 2018;169:JC2.
    >> Share

  101. MADENIDOU AV, Paschos P, Karagiannis T, Katsoula A, et al
    Comparative Benefits and Harms of Basal Insulin Analogues for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.
    Ann Intern Med. 2018 Jul 10. pii: 2687651. doi: 10.7326/M18-0443.
    >> Share

    June 2018
  102. HIRSCH IB, Skyler JS
    Brief Commentary: Confusing Treatment Guidelines for Patients With Type 2 Diabetes.
    Ann Intern Med. 2018 Jun 26. pii: 2686099. doi: 10.7326/M18-1473.
    >> Share

  103. SCHROEDER EB, Karter AJ
    Brief Commentary: Glycemic Targets for Older Adults With Type 2 Diabetes.
    Ann Intern Med. 2018 Jun 26. pii: 2686097. doi: 10.7326/M18-1471.
    >> Share

  104. MILES DRB
    Brief Commentary: Social Determinants of Health and Treatment Targets for Type 2 Diabetes.
    Ann Intern Med. 2018 Jun 26. pii: 2686098. doi: 10.7326/M18-1472.
    >> Share

  105. BURKE BV, Hedin S
    Brief Commentary: Laboratory Accuracy of Hemoglobin A1c Ranges and Treatment Targets for Patients With Type 2 Diabetes.
    Ann Intern Med. 2018 Jun 26. pii: 2686219. doi: 10.7326/M18-1482.
    >> Share

  106. NARAYAN KMV, Jagannathan R
    Two in One: Diagnosing Type 2 Diabetes With Single-Sample Testing.
    Ann Intern Med. 2018 Jun 19. pii: 2685289. doi: 10.7326/M18-1477.
    >> Share

  107. SELVIN E, Wang D, Lee AK, Coresh J, et al
    Identifying Trends in Undiagnosed Diabetes in U.S. Adults.
    Ann Intern Med. 2018;168:900-901.
    >> Share

  108. PETERSEN MP, Cefalu WT
    Identifying Trends in Undiagnosed Diabetes in U.S. Adults.
    Ann Intern Med. 2018;168:900.
    >> Share

  109. SELVIN E, Wang D, Matsushita K, Grams ME, et al
    Prognostic Implications of Single-Sample Confirmatory Testing for Undiagnosed Diabetes: A Prospective Cohort Study.
    Ann Intern Med. 2018 Jun 19. pii: 2684927. doi: 10.7326/M18-0091.
    >> Share

    May 2018
  110. MOIST L
    In type 2 diabetes with CVD and kidney disease, empagliflozin reduced mortality and hospitalization.
    Ann Intern Med. 2018;168:JC52.
    >> Share

    April 2018
  111. BEKIARI E, Karagiannis T, Tsapas A
    In type 2 diabetes, weekly semaglutide reduced HbA1c and increased weight loss more than weekly exenatide ER.
    Ann Intern Med. 2018;168:JC46.
    >> Share

  112. VIGERSKY RA
    Continuous Glucose Monitoring in Patients With Type 2 Diabetes Receiving Insulin Injections.
    Ann Intern Med. 2018;168:528.
    >> Share

  113. BECK RW, Riddlesworth TD
    Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections.
    Ann Intern Med. 2018;168:526-527.
    >> Share

  114. HAAK T
    Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections.
    Ann Intern Med. 2018;168:525-526.
    >> Share

  115. CHAMBERLAIN JJ, Johnson EL, Leal S, Rhinehart AS, et al
    Cardiovascular Disease and Risk Management: Review of the American Diabetes Association Standards of Medical Care in Diabetes 2018.
    Ann Intern Med. 2018 Apr 3. pii: 2677350. doi: 10.7326/M18-0222.
    >> Share

    March 2018
  116. GOEL A
    Intensive weight management in primary care improved weight loss and remission of type 2 diabetes.
    Ann Intern Med. 2018;168:JC30.
    >> Share


  117. Hemoglobin A1c Targets for Nonpregnant Adults With Type 2 Diabetes Mellitus.
    Ann Intern Med. 2018 Mar 6. pii: 2674123. doi: 10.7326/P18-0003.
    >> Share

  118. QASEEM A, Wilt TJ, Kansagara D, Horwitch C, et al
    Hemoglobin A1c Targets for Glycemic Control With Pharmacologic Therapy for Nonpregnant Adults With Type 2 Diabetes Mellitus: A Guidance Statement Update From the American College of Physicians.
    Ann Intern Med. 2018 Mar 6. pii: 2674121. doi: 10.7326/M17-0939.
    >> Share

    January 2018
  119. GENERE N, Montori VM
    Review: Newer second-line drugs for diabetes are not more cost-effective than sulfonylureas.
    Ann Intern Med. 2018;168:JC8.
    >> Share

    December 2017
  120. LIPSCOMBE LL
    Exenatide did not reduce major cardiovascular outcomes in type 2 diabetes.
    Ann Intern Med. 2017;167:JC67.
    >> Share

  121. LIPSCOMBE LL
    Liraglutide reduced a composite renal outcome at a median 4 y in patients with type 2 diabetes and high CV risk.
    Ann Intern Med. 2017;167:JC66.
    >> Share


  122. Cost-Effectiveness of Individualized Management of Diabetes Among U.S. Adults.
    Ann Intern Med. 2017 Dec 12. pii: 2665905. doi: 10.7326/P17-9050.
    >> Share

  123. LAITEERAPONG N, Cooper JM, Skandari MR, Clarke PM, et al
    Individualized Glycemic Control for U.S. Adults With Type 2 Diabetes: A Cost-Effectiveness Analysis.
    Ann Intern Med. 2017 Dec 12. pii: 2665902. doi: 10.7326/M17-0537.
    >> Share

    October 2017
  124. SELVIN E, Wang D, Lee AK, Bergenstal RM, et al
    Identifying Trends in Undiagnosed Diabetes in U.S. Adults by Using a Confirmatory Definition: A Cross-sectional Study.
    Ann Intern Med. 2017 Oct 24. doi: 10.7326/M17-1272.
    >> Share

  125. CONLIN PR, Colburn J, Aron D, Pries RM, et al
    Synopsis of the 2017 U.S. Department of Veterans Affairs/U.S. Department of Defense Clinical Practice Guideline: Management of Type 2 Diabetes Mellitus.
    Ann Intern Med. 2017 Oct 24. doi: 10.7326/M17-1362.
    >> Share

  126. PETERS AL
    Rethinking Rates of Undiagnosed Diabetes: The Value of a Confirmatory Test.
    Ann Intern Med. 2017 Oct 24. doi: 10.7326/M17-2576.
    >> Share

  127. DASGUPTA I, Singh AK
    Review: In diabetes, intensive and standard glycemic control do not differ for end-stage kidney disease or death.
    Ann Intern Med. 2017;167:JC47.
    >> Share

  128. MURFF HJ
    Self-monitoring of blood glucose did not improve HbA1c or QoL at 1 year in non-insulin-treated type 2 diabetes.
    Ann Intern Med. 2017;167:JC46.
    >> Share

    September 2017
  129. CHAMBERLAIN JJ, Kalyani RR, Leal S, Rhinehart AS, et al
    Treatment of Type 1 Diabetes: Synopsis of the 2017 American Diabetes Association Standards of Medical Care in Diabetes.
    Ann Intern Med. 2017 Sep 12. doi: 10.7326/M17-1259.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016